Views and experiences of hepatitis C testing and diagnosis among people who inject drugs: Systematic review of qualitative research

International Journal of Drug Policy

Volumn 25, Issue 2, 2014, Pages 204-211

  Jones, L ^a   Atkinson, A ^a   Bates, G ^a   McCoy, E ^a   Porcellato, L ^a   Beynon, C ^a   McVeigh, J ^a   Bellis, M A ^b  

^a LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^b PUBLIC HEALTH WALES   (United Kingdom)

Author keywords

Hepatitis C; Injecting drug use; Qualitative synthesis; Screening

Indexed keywords

ANXIETY; ATTITUDE TO ILLNESS; CONFUSION; DIAGNOSTIC TEST; HEALTH CARE DISPARITY; HEALTH CARE NEED; HEALTH CARE UTILIZATION; HEALTH EDUCATION; HEPATITIS C; HUMAN; INJECTION; MASS SCREENING; MEDICAL INFORMATION; PATIENT ASSESSMENT; PERSONAL EXPERIENCE; PRIORITY JOURNAL; QUALITATIVE RESEARCH; SHORT SURVEY; SYSTEMATIC REVIEW; ATTITUDE TO HEALTH; COMPLICATION; DIAGNOSTIC PROCEDURE; PSYCHOLOGY; SUBSTANCE ABUSE;

DIAGNOSTIC TECHNIQUES AND PROCEDURES; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEPATITIS C; HUMANS; QUALITATIVE RESEARCH; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84896088406     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2013.11.004     Document Type: Short Survey

References (54)

1. Astone J.M., Strauss S.M., Munoz-Plaza C., Hagan H., Des Jarlais D.C. Providing support to drug users infected with hepatitis C: The role of methadone maintenance treatment staff. Journal of Maintenance in the Addictions 2005, 3(1):33-46.
2. Bruce R.D. One stop shopping - Bringing services to drug users. Journal of International Drug Policy 2012, 23:103-110.
3. Bruggman P. Accessing Hepatitis C patients who are difficult to reach: It is time to overcome barriers. Journal of Viral Hepatitis 2012, 19:829-835.
4. Carrier N., LaPlante J., Bruneau J. Exploring the contingent reality of biomedicine: Injecting drug users, hepatitis C virus and risk. Health, Risk & Society 2005, 7(2):123-140.
5. Copeland L. The drug user's identity and how it relates to being Hepatitis C antibody positive: A qualitative study. Drugs-Education Prevention and Policy 2004, 11(2):129-147.
6. Corey K.E., Mendez-Navarro J., Gorospe E.C., Zheng H., Chung R.T. Early treatment improves outcomes in acute hepatitis C virus infection: A meta-analysis. Journal of Viral Hepatitis 2010, 17:201-207.
7. Craine N., Walker M., Carnwath T., Klee H. Hepatitis C testing and injecting risk behaviour: The results of a UK based pilot study. International Journal of Drug Policy 2004, 15(2):115-122.
8. Cullen B.L., Hutchinson S.J., Cameron S.O., Anderson E., Ahmed S., Spence E., et al. Identifying former injecting drug users infected with hepatitis C: An evaluation of a general practice-based case-finding intervention. Journal of Public Health 2012, 34(1):14-23.
9. Cullen W., Kelly Y., Stanley J., Langton D., Bury G. Experience of hepatitis C among current or former heroin users attending general practice. Irish Medical Journal 2005, 98(3):73-74.
10. Cullen W., Stanley J., Langton D. Hepatitis C infection among injecting drug users in general practice: A cluster randomised controlled trial of clinical guidelines' implementation. British Journal of General Practice 2006, 56(532):848-856.
11. Davis M., Rhodes T. Beyond prevention? Injecting drug user narratives about hepatitis C. International Journal of Drug Policy 2004, 15(2):123-131.
12. Davis M., Rhodes T., Martin A. Preventing hepatitis C: 'Common sense', 'the bug' and other perspectives from the risk narratives of people who inject drugs. Social Science & Medicine 2004, 59(9):1807-1818.
13. Ellard J. 'There is no profile it is just everyone': The challenge of targeting hepatitis C education and prevention messages to the diversity of current and future injecting drug users. International Journal of Drug Policy 2007, 18(3):225-234.
14. Faye B., Irurita V.F. Balancing perspective: The response to feelings of being condemned with the hepatitis C virus. Journal of Substance Use 2003, 8(2):92-103.
15. Grebely J., de Vlaming S., Duncan F., Viljoen M., Conway B. Current approaches to HCV infection in current and former injection drug users. Journal of Addictive Diseases 2008, 27(2):25-35.
16. Grebely J., Dore G.J. Hepatitis C: Enhancing treatment for hepatitis C among drug users. Nature Reviews Gastroenterology and Hepatology 2011, 8:11-13.
17. Gyarmathy V.A., Neaigus A., Ujhelyi E., Szabo T., Racz J. Strong HIV and hepatitis disclosure norms and frequent risk behaviors among Hungarian drug injectors. Drug & Alcohol Dependence 2006, 82(Suppl. 1):S65-S69.
18. Harris M. Injecting, infection, illness: Abjection and hepatitis C stigma. Body & Society 2009, 15(4):33-51.
19. Harris M. Troubling biographical disruption: Narratives of unconcern about hepatitis C diagnosis. Sociology of Health & Illness 2009, 31(7):1028-1042.
20. Harris M., Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: A review mapping the role of social factors. Harm Reduction Journal 2013, 10:7.
21. Hatzakis A., Wait S., Bruix J., Buti M., Carballo M., Cavaleri M., et al. The state of hepatitis B and C in Europe: Report from the hepatitis B and C summit conference. Journal of Viral Hepatitis 2011, 18(Suppl. 1):1-16.
22. Helsper C.W., van Essen G.A., Bonten M.J.M., de Wit N.J. A support programme for primary care leads to substantial improvements in the effectiveness of a public hepatitis C campaign. Family Practice 2010, 27(3):328-332.
23. Hickman M., McDonald T., Judd A., Nichols T., Hope V., Skidmore S., et al. Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: A cluster randomized controlled trial. Journal of Viral Hepatitis 2008, 15(4):250-254.
24. Hopwood M., Treloar C. Receiving a hepatitis C-positive diagnosis. Internal Medicine Journal 2004, 34:526-531.
25. Jack K., Willott S., Manners J., Varnam M.A., Thomson B.J. Clinical trial: A primary-care-based model for the delivery of anti-viral treatment to injecting drug users infected with hepatitis C. Alimentary Pharmacology & Therapeutics 2009, 29(1):38-45.
26. Jones L., Bates G., McCoy E., Beynon C., McVeigh J., Bellis M.A. Effectiveness of interventions to increase hepatitis C testing uptake among high-risk groups: A systematic review. European Journal of Public Health 2013, 10.1093/eurpub/ckt156.
27. Khaw F.-M., Stobbart L., Murtagh M.J. 'I just keep thinking I haven't got it because I'm not yellow': A qualitative study of the factors that influence the uptake of Hepatitis C testing by prisoners. BMC Public Health 2007, 7:98.
28. Lally M.A., Montstream-Quas S.A., Tanaka S., Tedeschi S.K., Morrow K.M. A qualitative study among injection drug using women in Rhode Island: attitudes toward testing, treatment, and vaccination for hepatitis and HIV. AIDS Patient Care and STDs 2008, 22(1):53-64.
29. Lindenburg C.E.A., Lambers F.A.E., Urbanus A.T., Schinkel J., Jansen P.L.M., Krol A., et al. Hepatitis C testing and treatment among active drug users in Amsterdam: Results from the DUTCH-C project. European Journal of Gastroenterology & Hepatology 2011, 23(1):23-31.
30. Morris K. Tackling hepatitis C: A tale of two countries. The Lancet 2011, 377:1227-1228.
31. Mühlberger N., Schwarzer R., Lettmeier B., Sroczynski G., Zeuzem S., Siebert U. HCV-related burden of disease in Europe: A systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health 2009, 9:34.
32. Munoz-Plaza C.E., Strauss S.M., Astone J.M., Des Jarlais D.C., Hagan H. HCV (Hepatitis C virus) pre-test and post-test counseling services at drug treatment programs: Missed opportunities for primary prevention. Contemporary Drug Problems: An Interdisciplinary Quarterly 2005, 32(4):655-675.
33. Munoz-Plaza C.E., Strauss S.M., Astone J.M., Jarlms D.C.D., Hagan H. Drug treatment programs as sites of opportunity for the delivery of hepatitis C prevention education: Client and staff perspectives. Journal of Drug Issues 2004, 34(4):861-878.
34. Munoz-Plaza C., Strauss S.M., Tiburcio N., Astone-Twerell J.M., Des Jarlais D.C., Gwadz M., et al. Perspectives on the hierarchy of HIV and hepatitis C disease: Consequences for drug treatment program patients. Journal of Drug Issues 2010, 40(2):517-535.
35. National Institute for Health and Clinical Excellence Methods for the development of NICE public health guidance 2009, National Institute for Health and Clinical Excellence, London. 2 ed.
36. Nelson P.K., Mathers B.M., Cowie B., Hagan H., Des Jarlais D., Horyniak D., et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews. The Lancet 2011, 378(9791):571-583.
37. Perry M., Chew-Graham C. Finding a vein or obtaining consent: A qualitative study of hepatitis C testing in GP methadone clinics. Family Practice 2003, 20(5):538-544.
38. Rhodes T., Davis M., Judd A. Hepatitis C and its risk management among drug injectors in London: Renewing harm reduction in the context of uncertainty. Addiction 2004, 99(5):621-633.
39. Rhodes T., Treloar C. The social production of hepatitis C risk 567 among injecting drug users: A qualitative synthesis. Addiction 2008, 103(10):1593-1603.
40. Roy E., Nonn E., Haley N., Cox J. Hepatitis C meanings and preventive strategies among street-involved young injection drug users in Montreal. International Journal of Drug Policy 2007, 18(5):397-405.
41. Southgate E., Weatherall A.M., Day C., Dolan K.A. What's in a virus? Folk understandings of hepatitis C infection and infectiousness among injecting drug users in Kings Cross, Sydney. International Journal for Equity in Health 2005, 4(5.). http://dx.doi.org/10.1186/1475-9276-4-5.
42. Strauss S.M., Munoz-Plaza C., Tiburcio N.J., Astone-Twerell J., Des Jarlais D.C., Gwadz M., et al. Barriers and facilitators to undergoing hepatitis C virus (HCV) testing through drug treatment programs. Journal of Drug Issues 2008, 38(4):1161-1185.
43. Sutton R., Treloar C. Chronic illness experiences, clinical markers and living with hepatitis C. Journal of Health Psychology 2007, 12(2):330-340.
44. Swan D., Long J., Carr O., Flanagan J., Irish H., Keating S., et al. Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: A qualitative exploration. AIDS Patient Care and STDs 2010, 24(12):753-762.
45. Temple-Smith M., Gifford S., Stoové M. The lived experience of men and women with hepatitis C: Implications for support needs and health information. Australian Health Review 2004, 27(2):46-56.
46. Thomas J., Harden A. Methods for the thematic synthesis of qualitative research in systematic reviews. BMC Medical Research Methodology 2008, 8:45.
47. Tompkins C.N.E., Wright N.M.J., Jones L. Impact of a positive hepatitis C diagnosis on homeless injecting drug users: A qualitative study. British Journal of General Practice 2005, 55(513):263-268.
48. Treloar C., Newland J., Harris M., Deacon R., Maher L. A diagnosis of hepatitis C: Insights from a study on patients' experiences. Australian Family Physician 2010, 39(8):589-592.
49. Treloar C., Rance J., Backmund M. Understanding barriers to hepatitis C virus care and stigmatization from a social perspective. Clinical Infectious Diseases 2013, 57(Suppl. 2):S51-S55.
50. Volk M.L., Tocco R., Saini S., Lok A.S. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 2009, 50(6):1750-1755.
51. World Health Organization Prevention and control of viral hepatitis infection: Framework for global action 2012, World Health Organisation, Geneva.
52. World Health Organization Guidance of the prevention of viral hepatitis B and C among people who inject drugs 2012, World Health Organisation, Geneva.
53. Wozniak L., Prakash M., Taylor M., Wild T.C. Everybody's got it, but. .: Situational and strategic participation in normalized HCV discourse among injection drug users in Edmonton, Canada. International Journal of Drug Policy 2007, 18(5):388-396.
54. Wright N.M.J., Tompkins C.N.E., Jones L. Exploring risk perception and behaviour of homeless injecting drug users diagnosed with hepatitis C. Health & Social Care in the Community 2005, 13(1):75-83.